THIS ANNOUNCEMENT, INCLUDING THE INFORMATION CONTAINED HEREIN,
IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,
IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE
UNITED STATES, CANADA, JAPAN, AUSTRALIA, NEW ZEALAND, THE REPUBLIC
OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR ANY OTHER JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF THAT JURISDICTION.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND SHALL
NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION OF AN
OFFER TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY NEW ORDINARY
SHARES OF ONCIMMUNE HOLDINGS PLC IN THE UNITED STATES, CANADA,
JAPAN, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA, THE
REPUBLIC OF IRELAND OR ANY OTHER JURISDICTION IN WHICH SUCH
RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN
ARTICLE 7 OF THE MARKET ABUSE REGULATION EU NO 596/ 2014, AS
RETAINED AND APPLICABLE IN THE UK PURSUANT TO S3 OF THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018 ("MAR"). IN ADDITION, MARKET SOUNDINGS
(AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS
CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN
PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION, AS PERMITTED BY
MAR. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF
INSIDE INFORMATION.
TERMS NOT OTHERWISE DEFINED HEREIN SHALL HAVE THE MEANINGS
GIVEN TO THEM IN THE COMPANY'S ANNOUNCEMENT RELEASED AT 7:47 A.M.
ON 18 OCTOBER 2024.
Oncimmune Holdings plc
("Oncimmune" or the
"Company")
Result of Placing & Issue of
Equity
Oncimmune Holdings plc (AIM: ONC.L),
a leading autoantibody profiling company providing research
services to the pharmaceutical and biotechnology industry to enable
the delivery of precision medicine is pleased to announce that
further to the Company's announcement released at 7.47 a.m. this
morning (the "Launch
Announcement"), the ABB has closed and the Company has
conditionally raised gross proceeds of approximately £2.15 million,
through the successful Placing of 12,000,00 Placing Shares
(comprising 5,500,000 Firm Placing Shares and 6,500,000 Conditional
Placing Shares) as well as a Subscription of a minimum of 2,333,333
new Ordinary Shares at the Issue Price of 15 pence per Ordinary
Share.
In addition to the Placing and
Subscription, the Company is providing its retail shareholder base
with the opportunity to subscribe for an aggregate of up to
2,000,000 Retail Offer Shares at the Issue Price, to raise up to
£0.3 million.
The Firm
Placing and Firm Subscription are not
conditional on the passing of the Resolutions at the General
Meeting though are conditional on First Admission
and upon the Placing Agreement not being
terminated prior to First Admission. It is
expected that First Admission will occur, and that dealings in the
Firm Placing Shares and Firm Subscription Shares will become
effective on 23 October 2024.
The Conditional Placing, Conditional
Subscription and Retail Offer are conditional upon, inter alia, the passing of the
Resolutions at the General Meeting, Second Admission and upon the
Placing Agreement becoming unconditional in all
respects. It is expected that Second
Admission will occur, and that dealings in the Conditional Placing
Shares, Conditional Subscription Shares, Conversion Shares and the
Retail Offer Shares will become effective on 11 November 2024.
No part of the Placing or
Subscription is conditional on the Retail Offer proceeding or on
any minimum take-up under the Retail Offer.
General Meeting and Shareholder Approval
In order to obtain the necessary
shareholder approval, a General Meeting is to be held at the
offices of Cavendish Financial Plc, 1
Bartholomew Close, London EC1A 7BL at 11.00 a.m.
on 8 November 2024
at which the Resolutions will be proposed. A Circular containing a
notice of General Meeting is expected to be sent to shareholders on
or around 22 October 2024. The shareholder Circular and notice of General Meeting
will be made available on the Company's website
at https://www.oncimmune.com/investors/documents/.
Admission, settlement and dealings
Application has been made for
admission of the 5,500,000 Firm Placing Shares and 500,000 Firm
Subscription Shares to be admitted to trading on AIM. First
Admission is expected to take place at 8.00 a.m. on 23 October
2024. Following First Admission, the Company will have 80,142,147
Ordinary Shares in issue carrying voting rights. This figure may be
used by Shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change of their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.
Following closing of the Retail
Offer, the Company will make an application for the Conditional
Placing Shares, Conditional Subscription Shares, Conversion Shares
and the Retail Offer Shares to be admitted to trading on AIM on
Second Admission, which is expected to occur on 11 November 2024. A
further announcement will be made in due course.
For
further information:
Oncimmune Holdings plc
contact@oncimmune.com
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
Geoff Nash, Callum Davidson, Trisyia
Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist
Sales)
Ondraya Swanson (ECM)
+44 (0) 20 7220 0500
Zeus (Joint Broker)
Dominic King, Dan Bate
+44 (0)20 3829 5000